Royalty Pharma Plc (RPRX) Superinvestor holders
26 of the superinvestors we track hold Royalty Pharma Plc (RPRX) in their latest 13F filings, $1.7B in total.
Summary
The largest holder is Baillie Gifford (Baillie Gifford & Co), with $534M, 0.5% of the portfolio.
In their latest quarter: 4 opened a new position, 11 added, 10 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Baillie Gifford Baillie Gifford & Co |
Trimmed | 9,151,948 | $534M | 0.5% | Q3 2026 |
| Cliff Asness AQR Capital Management |
Added | 4,305,412 | $241M | 0.1% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 2,920,163 | $164M | 0.1% | Q2 2026 |
| Pat Dorsey Dorsey Asset Management |
Added | 2,456,528 | $138M | 8.8% | Q2 2026 |
| Paul Marshall Marshall Wace |
Added | 2,450,669 | $137M | 0.1% | Q2 2026 |
| Arrowstreet Capital | Added | 2,435,341 | $137M | 0.1% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Added | 1,935,800 | $109M | 0.1% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Trimmed | 610,736 | $34M | 0.1% | Q2 2026 |
| Robert Torray Torray Investment Partners |
Trimmed | 564,461 | $33M | 4.3% | Q3 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 525,114 | $29M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 426,592 | $24M | 0.0% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Added | 344,861 | $19M | 0.2% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
New position | 219,687 | $12M | 0.1% | Q2 2026 |
| Will Nasgovitz Heartland Advisors |
Trimmed | 204,398 | $11M | 0.5% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 166,593 | $9M | 0.0% | Q2 2026 |
| Thornburg Thornburg Investment Management |
Added | 123,122 | $7M | 0.1% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
Trimmed | 106,549 | $6M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Added | 82,435 | $5M | 0.1% | Q2 2026 |
| David Vogel Voloridge Investment Management |
New position | 52,561 | $3M | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
New position | 35,176 | $2M | 0.1% | Q2 2026 |
| Alger Fred Alger Management |
Added | 34,725 | $2M | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 21,400 | $1M | 5.7% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 7,968 | $464,000 | 0.0% | Q3 2026 |
| Brandon Haley Holocene Advisors |
Trimmed | 4,728 | $265,099 | 0.0% | Q2 2026 |
| Ken Tropin Graham Capital Management |
New position | 4,716 | $264,426 | 0.0% | Q2 2026 |
| Aziz Hamzaogullari Loomis Sayles & Co |
Added | 1,971 | $110,514 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 26 |
| Q1 2026 | 23 |
| Q4 2025 | 18 |
| Q3 2025 | 18 |
| Q2 2025 | 15 |
| Q1 2025 | 14 |
| Q4 2024 | 15 |
| Q3 2024 | 13 |
Questions about Royalty Pharma Plc
Which superinvestors own Royalty Pharma Plc?
26 of the superinvestors we track hold Royalty Pharma Plc (RPRX) in their latest 13F filings, $1.7B in total. Baillie Gifford, Cliff Asness, Two Sigma, Pat Dorsey, Paul Marshall, Arrowstreet Capital.
Who is the largest superinvestor holder of RPRX?
The largest holder is Baillie Gifford (Baillie Gifford & Co), with $534M, 0.5% of the portfolio.
From Royalty Pharma Plc's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.